Link Pharma Chem Ltd
₹ 36.1
2.44%
23 May
- close price
About
Incorporated in 1986, Link Pharma Chem Ltd is engaged in the manufacturing and job work of organic intermediates.
Key Points
- Market Cap ₹ 16.0 Cr.
- Current Price ₹ 36.1
- High / Low ₹ 50.9 / 28.2
- Stock P/E
- Book Value ₹ 30.9
- Dividend Yield 0.00 %
- ROCE -4.79 %
- ROE -10.0 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.17 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.06% over past five years.
- Company has a low return on equity of 1.34% over last 3 years.
- Debtor days have increased from 44.6 to 62.9 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Upcoming result date: 27 May 2025
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
16.36 | 23.59 | 17.58 | 12.35 | 16.10 | 23.53 | 24.50 | 25.47 | 34.81 | 53.56 | 38.76 | 29.90 | 27.02 | |
14.20 | 21.25 | 18.36 | 12.16 | 13.56 | 20.75 | 22.48 | 22.05 | 31.67 | 50.02 | 36.04 | 30.55 | 25.75 | |
Operating Profit | 2.16 | 2.34 | -0.78 | 0.19 | 2.54 | 2.78 | 2.02 | 3.42 | 3.14 | 3.54 | 2.72 | -0.65 | 1.27 |
OPM % | 13.20% | 9.92% | -4.44% | 1.54% | 15.78% | 11.81% | 8.24% | 13.43% | 9.02% | 6.61% | 7.02% | -2.17% | 4.70% |
0.15 | 0.26 | 0.21 | 2.39 | -0.43 | 0.07 | 0.19 | -0.69 | -0.15 | 0.46 | -0.15 | 0.64 | 0.06 | |
Interest | 1.21 | 1.14 | 1.44 | 0.91 | 0.80 | 0.62 | 0.39 | 0.36 | 0.44 | 0.45 | 0.76 | 0.87 | 0.83 |
Depreciation | 0.60 | 0.79 | 1.13 | 0.93 | 0.83 | 0.86 | 0.89 | 0.93 | 0.87 | 0.93 | 0.92 | 1.03 | 0.97 |
Profit before tax | 0.50 | 0.67 | -3.14 | 0.74 | 0.48 | 1.37 | 0.93 | 1.44 | 1.68 | 2.62 | 0.89 | -1.91 | -0.47 |
Tax % | 42.00% | 23.88% | -29.94% | 20.27% | 54.17% | 17.52% | 29.03% | 34.03% | 35.12% | 28.24% | 26.97% | -28.80% | |
0.29 | 0.52 | -2.20 | 0.59 | 0.23 | 1.13 | 0.66 | 0.95 | 1.08 | 1.88 | 0.65 | -1.36 | -0.42 | |
EPS in Rs | 0.65 | 1.17 | -4.95 | 1.33 | 0.52 | 2.54 | 1.49 | 2.14 | 2.43 | 4.23 | 1.46 | -3.06 | -0.94 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 4% |
3 Years: | -5% |
TTM: | -13% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 77% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 19% |
3 Years: | -7% |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 5% |
3 Years: | 1% |
Last Year: | -10% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 |
Reserves | 5.71 | 6.23 | 3.93 | 4.52 | 4.16 | 5.35 | 5.94 | 6.99 | 8.12 | 10.03 | 10.60 | 9.27 | 9.28 |
8.94 | 9.08 | 10.80 | 5.41 | 4.73 | 2.71 | 2.64 | 3.56 | 3.66 | 6.39 | 8.76 | 9.22 | 8.20 | |
6.04 | 6.60 | 7.35 | 3.46 | 3.81 | 4.69 | 4.99 | 3.98 | 9.82 | 8.10 | 8.66 | 3.02 | 4.53 | |
Total Liabilities | 25.13 | 26.35 | 26.52 | 17.83 | 17.14 | 17.19 | 18.01 | 18.97 | 26.04 | 28.96 | 32.46 | 25.95 | 26.45 |
13.82 | 14.59 | 17.51 | 10.13 | 9.57 | 9.76 | 9.14 | 8.81 | 8.71 | 8.79 | 9.00 | 9.94 | 9.60 | |
CWIP | 1.53 | 1.92 | 0.00 | 0.00 | 0.00 | 0.01 | 0.43 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 |
Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 4.52 | 3.64 | 2.93 | 3.63 |
9.76 | 9.82 | 8.99 | 7.68 | 7.54 | 7.39 | 8.41 | 10.13 | 17.30 | 15.44 | 19.82 | 13.08 | 13.22 | |
Total Assets | 25.13 | 26.35 | 26.52 | 17.83 | 17.14 | 17.19 | 18.01 | 18.97 | 26.04 | 28.96 | 32.46 | 25.95 | 26.45 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.84 | 0.87 | 5.13 | -3.91 | 2.23 | 3.79 | 1.36 | 2.95 | 4.84 | -1.26 | -1.71 | -0.03 | |
-0.62 | -1.14 | -3.27 | 8.72 | -0.73 | -1.15 | -0.96 | -1.66 | -2.16 | -4.97 | -0.08 | 0.41 | |
1.35 | 0.30 | -0.87 | -5.75 | -1.48 | -2.63 | -0.46 | 0.55 | -0.33 | 2.27 | 1.61 | -0.41 | |
Net Cash Flow | -0.11 | 0.03 | 0.99 | -0.94 | 0.02 | 0.00 | -0.05 | 1.85 | 2.35 | -3.95 | -0.17 | -0.03 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 71.62 | 51.06 | 63.74 | 68.86 | 49.42 | 49.33 | 45.29 | 71.51 | 58.19 | 36.60 | 34.18 | 62.87 |
Inventory Days | 261.84 | 143.28 | 125.34 | 277.34 | 285.97 | 96.96 | 92.54 | 60.04 | 51.35 | 47.68 | 209.23 | 135.89 |
Days Payable | 98.25 | 110.60 | 94.59 | 81.61 | 202.93 | 124.25 | 108.98 | 110.86 | 140.70 | 45.37 | 112.90 | 38.51 |
Cash Conversion Cycle | 235.20 | 83.74 | 94.49 | 264.59 | 132.47 | 22.05 | 28.85 | 20.68 | -31.16 | 38.90 | 130.51 | 160.24 |
Working Capital Days | 87.90 | 52.14 | 39.45 | 91.32 | 75.49 | 34.59 | 41.27 | 51.45 | 15.73 | 37.96 | 90.59 | 104.74 |
ROCE % | 9.75% | 9.32% | -8.74% | -3.64% | 13.00% | 15.41% | 10.34% | 18.71% | 14.61% | 13.16% | 6.72% | -4.79% |
Documents
Announcements
-
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended On March 31, 2025, Under Regulation 29(1) Of The SEBI (LODR) Regulations, 2015.
17 May - Board meeting on May 27, 2025, to approve audited Q4 and FY2025 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - Confirmation Certificate under Regulation 74(5) for Q1 2025.
- Closure of Trading Window 25 Mar
-
Intimation As Per Regulation 30 & 31A Of SEBI (LODR) Regulation, 2015.
25 Feb - Rejection of reclassification application by BSE Limited.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Feb - Newspaper Advertisements of Unaudited Financial Results for the quarter and nine months ended December 31, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and exports multi range intermediates for pharmaceutical, agro industries and specialty chemicals. It is also engaged in custom synthesis/contract manufacturing for multistage synthesis for small, medium, large companies.